Routine annual meeting filing with no material financial news. Monitor future equity grants for dilution, but no immediate trading catalyst.
Price Chart
Executive Summary
Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Shareholders approved amendments to the 2018 Equity Incentive Plan and 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares respectively, and ratified Ernst & Young as auditor. No director departures or officer changes occurred.
Key Facts
- Shareholders approved amendment to 2018 Equity Incentive Plan, adding 500,000 shares
- Shareholders approved amendment to 2000 Employee Stock Purchase Plan, adding 360,000 shares
- All three director nominees (Hannah, Moos, Rodriguez) were elected
- Say-on-pay and ratification of Ernst & Young as auditor passed
- No departures, appointments, or material financial disclosures
Financial Impact
No immediate financial impact; potential future dilution from ~860,000 newly authorized shares under equity plans
Risk Factors
- Potential future dilution from equity plan shares
- No forward guidance or operational updates provided
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000041 |
| Document: 0001034842-26-000041-index.html | 0001034842-26-000041 |
| Document: 0001034842-26-000041.txt | 0001034842-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $40.48 $49.42 | ▲ +22.09% | ▲ +22.69% | $46.50 (+14.87%) |
Jun 17, 2026 15w ago | 8-K | $32.91 $41.67 | ▲ +26.62% | ▲ +26.09% | $46.50 (+41.29%) |
Jun 11, 2026 16w ago | Institutional Cluster | $32.08 $43.76 | ▲ +36.41% | ▲ +34.52% | $46.50 (+44.95%) |
May 20, 2026 19w ago | 8-K | $29.19 $35.78 | ▲ +22.58% | ▲ +22.24% | $46.50 (+59.30%) |
May 12, 2026 20w ago | 8-K | $32.13 $32.08 | ▼ −0.16% | ▲ +0.46% | $46.50 (+44.72%) |
May 5, 2026 21w ago | 8-K | $26.67 $30.30 | ▼ −13.61% | ▼ −10.83% | $46.50 (−74.35%) |
Apr 21, 2026 23w ago | 8-K | $30.47 $28.30 | ▲ +7.12% | ▲ +10.29% | $46.50 (−52.61%) |
Apr 3, 2026 25w ago | DEFA14A | $27.36 $29.54 | ▲ +7.97% | ▼ −1.01% | $46.50 (+69.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access